Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers are actively testing psilocybin (the active part of “magic mushrooms”) as a possible treatment for several mental health problems. Early clinical trials—usually done under medical supervision with therapy before and after the drug session—have found quick improvements in some people with major depression, anxiety linked to serious illness, and other hard-to-treat conditions (but the studies are still small). (15135,15063,15056) Scientists propose several ways psilocybin might help, such as changing how brain networks communicate, boosting the brain’s ability to form new connections, and lowering brain inflammation. However, the exact reasons are not settled. Safety in careful clinical settings looks acceptable so far, but harms may be underreported, and unsupervised use can carry real risks. More and larger trials are needed, and many groups (for example people of color) were not well represented in early studies. (15132,15050,15135,15061,15095,15056)
This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…
This review explains the fast-growing problem of so-called "legal highs", which are better called novel psychoactive substances or NPS. Unknown labs keep making slightly different chemicals to avoid bans, and this led to about 80 new substances being spotted in one year. The paper groups these drugs into five main…
This paper looked across existing studies of psilocybin and found that, when it is given along with psychotherapy or therapy-style support, it looks promising as a treatment for several mental health problems, including cases that did not get better with other treatments. But the authors say the current studies are…
This paper reviews what scientists know about how ketamine and classic serotonergic psychedelics (like psilocybin and LSD) can lift depression quickly. The authors compare how the drugs work in the brain, point out that ketamine has the strongest clinical evidence so far, and say psychedelics show early promise but need…
This paper explains how different hallucinogens change thinking, perception, and mood by acting on different brain targets. Some well-known drugs like LSD, psilocybin, and DMT mainly affect the brain chemical serotonin. Others work by blocking NMDA receptors, by activating opioid receptors, or by keeping chemicals like serotonin, norepinephrine, and dopamine…
This paper is a first look at whether the fast-acting psychedelic 5‑MeO‑DMT might help people with alcohol use disorder. The authors reviewed existing studies in humans and animals and found early signs that 5‑MeO‑DMT can cause intense mystical feelings and a loss of self-boundaries, and that it changes brain rhythms…
This review looks at how psilocybin mushrooms and their active ingredient psilocin might affect the brain and mental health. The authors say that brain inflammation seems to play a role in many cases of depression and anxiety. Lab and clinical studies show that psilocin can lower brain inflammation, boost the…
